{"id":"W4402561305","doi":"10.1016/j.annonc.2024.08.384","title":"437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Antibody-drug conjugate; Open label; Conjugate; Trastuzumab; Drug; Oncology; Pharmacology; Phases of clinical research; Internal medicine; Antibody; Clinical trial; Monoclonal antibody; Adverse effect; Cancer; Immunology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001057591,0.0009990922,0.001639581,0.0003307954,0.0003718252,0.0009014746,0.0006686408,0.0009870962,0.005659769],"category_scores_gemma":[0.0005902059,0.0004071912,0.0008348559,0.0003607449,0.0008037745,0.0006564817,0.0002672916,0.003275259,0.001520791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000747584,"about_ca_system_score_gemma":0.001668677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00111833,"about_ca_topic_score_gemma":0.002062249,"domain_scores_codex":[0.999631,0.0001641271,0.00001421721,0.00006631663,0.00003748777,0.00008677145],"domain_scores_gemma":[0.999415,0.00009089072,0.00008296494,0.00005001587,0.00004195862,0.0003192289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6333577,0.08936252,0.008659073,0.0007354791,0.001243245,0.0003028816,0.0002481985,0.002269148,0.09196278,0.0005625042,0.007403444,0.163893],"study_design_scores_gemma":[0.3354689,0.6377372,0.01169837,0.00003288206,0.0004432602,0.0003094225,0.00005631091,0.001734,0.007582225,0.0002160144,0.004689321,0.0000323002],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988257,0.002107293,0.001151351,0.0004426623,0.0001744368,0.002282002,0.001765584,0.0001607632,0.003658856],"genre_scores_gemma":[0.9823506,0.001585013,0.002825834,0.001490263,0.0002601382,0.002170303,0.004828928,0.00007444511,0.004414662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005659769,"threshold_uncertainty_score":0.01893377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1451483507414006,"score_gpt":0.5117613860980696,"score_spread":0.366613035356669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}